Form 4: Regeneron EVP McCourt Reports Equity Awards & Tax-Related Sale

Regeneron Pharmaceuticals' EVP Commercial, Marion McCourt, reported the acquisition of restricted stock and non-qualified stock options, alongside a tax-related disposition of common stock.

Summary

• Marion McCourt, EVP Commercial of Regeneron Pharmaceuticals, Inc. (REGN), reported transactions involving the company's equity securities.
• On December 5, 2025, McCourt acquired 2,476 shares of common stock as a Restricted Stock Award under the Second Amended and Restated 2014 Long-Term Incentive Plan.
• These restricted shares vest 50% on December 5, 2027, and the remaining 50% on December 5, 2029.
• Also on December 5, 2025, McCourt acquired 12,210 Non-Qualified Stock Options with an exercise price of $726.71.
• These stock options vest in four equal annual installments, commencing one year after the grant date, and expire on December 5, 2035.
• On December 8, 2025, McCourt disposed of 1,336 shares of common stock at a price of $712.94 per share, likely for tax withholding purposes related to an equity award.
• Following these transactions, McCourt directly beneficially owns 15,370 shares of common stock and 12,210 derivative securities (Non-Qualified Stock Options).
• Additionally, McCourt indirectly beneficially owns 197 shares of common stock through a 401(k) Plan.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation, including significant equity awards, which is generally a neutral to slightly positive signal as it aligns executive incentives with shareholder interests. The disposition of shares is for tax purposes, a common and expected event.

Positives

• The acquisition of 2,476 restricted stock units and 12,210 non-qualified stock options represents a significant equity award, aligning the executive's interests with long-term shareholder value.
• The vesting schedules for both the restricted stock (through 2029) and stock options (over four years) incentivize long-term commitment and performance from a key executive.

Negatives

• The disposition of 1,336 shares of common stock at $712.94 was likely for tax withholding purposes, which is a routine event associated with equity compensation and not indicative of a negative outlook.

Future Outlook

The filing details future vesting schedules for restricted stock and stock options, indicating a long-term incentive structure for the executive.

Industry Context

This Form 4 filing reflects routine executive compensation practices within the pharmaceutical industry, where equity awards like restricted stock and stock options are common tools to attract, retain, and incentivize key management personnel, aligning their financial interests with the company's long-term performance.

Comparison to Industry Standards

• The use of restricted stock awards and non-qualified stock options as part of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Bristol Myers Squibb.
• The vesting schedules, particularly the multi-year vesting for both restricted stock and options, are typical for senior executives, designed to promote long-term retention and performance, consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: The equity awards align the EVP Commercial's interests with long-term shareholder value, potentially fostering sustained performance.
• Employees: This filing provides transparency into executive compensation practices, which can influence overall employee morale and perception of fairness in compensation structures.

Next Steps

• The restricted stock will vest 50% on December 5, 2027, and the remaining 50% on December 5, 2029.
• The non-qualified stock options will vest in four equal annual installments, commencing one year after the grant date of December 5, 2025.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Transaction, Equity Compensation, Restricted Stock, Stock Options, Executive Compensation, Marion McCourt